This is the extract from the research on oral scopolamine. They used 1mg a day for oral dosing (the other studies used IV or IM but this one is oral which is easier for self-medding). You can see it is scopolamine hydrobromide (which is the same as hyoscine hydrobromide). It is not the butylbromide version as that doesn't cross the blood-brain barrier.
So I just got myself Kwells travel sickness tablets. Each tablet is 300 mg, so I am going to take 3 a day. Here is the source:
https://pubmed.ncbi.nlm.nih.gov/23146150/
The summary paper said it better:
Patients in the group receiving scopolamine had an average of 73.8% reduction in their HDRS score, while the group receiving the placebo had an average of 59.3% reduction in their HDRS score. Furthermore, 65% of patients assigned to the scopolamine-augmented schedule achieved remission, whereas this was the case with only 20% of patients'receiving citalopram alone.
Objective: To evaluate the antidepressant effect of oral scopolamine as an adjunct to citalopram.
Method: In this randomized double-blind placebo-controlled study, patients were assessed in the outpatient clinics of 2 large hospitals from November 2011 to January 2012. Forty patients (18-55 years) with major depressive disorder (DSM-IV-TR criteria) and 17-Item Hamilton Depression Rating Scale (HDRS) score ≥ 22 were randomly assigned to scopolamine hydrobromide (1 mg/d) (n = 20) or placebo (n = 20) in addition to citalopram for 6 weeks. HDRS score was measured at baseline and days 4, 7, 14, 28, and 42. The primary outcome measure was HDRS score change from baseline to week 6 in the scopolamine group versus the placebo group. Response was defined as ≥ 50% decrease in HDRS score; remission, as HDRS score ≤ 7.
Results: Augmentation with scopolamine was significantly more effective than placebo (F(1,38) = 5.831, P = .021). Patients receiving scopolamine showed higher rates of response (65%, 13/20 at week 4) and remission (65%, 13/20 at week 6) than the placebo group (30%, 6/20 and 20%, 4/20, respectively; P = .027, P = .004, respectively). Patients in the scopolamine group showed higher rates of dry mouth, blurred vision, and dizziness than the placebo group.
